Karachi: Liven Pharma Limited, previously known as Landmark Spinning Industries Limited, has announced a strategic initiative to issue 20 million right shares to its existing shareholders. The company aims to raise funds to bolster its operational capacity and support its growth trajectory. According to information available from the Pakistan Stock Exchange (PSX), the right issue is priced at PKR 10 per share, representing a 21.496% increase in the existing paid-up capital of the company. This move, approved by the Board of Directors on September 12, 2025, comes with the aim of enhancing the company's market position and financial health.
The total issue size is PKR 200.00 million, and the offer document was placed on the PSX for public comments. The final offer letter was issued on November 18, 2025, with book closure dated November 27, 2025. Subscription payments are scheduled between December 1 and December 22, 2025, while trading for the letter of rights will occur from December 1 to December 15, 2025. Muhammad Shah, the Chief Financial Officer of Liven Pharma, is the authorized contact for this initiative.
The primary utilization of the right issue proceeds includes establishing a Dry Powder Injectables (DPI) facility, procuring vehicles for an expanded sales force, and covering DRAP registration and licensing expenses. The DPI facility, with an estimated cost of PKR 40.00 million, aims to increase the company's production capacity by 300,000 units annually by June 2027. This facility will be situated at the company's existing location on Multan Road, Lahore.
An additional PKR 49.00 million will be allocated for vehicle procurement, enhancing sales force mobility and product visibility. The expansion of the sales team and promotional activities will utilize PKR 65.00 million, supporting the recruitment of 53 new sales professionals to increase outreach and brand visibility. Furthermore, PKR 40.00 million is set aside for additional working capital requirements, facilitating the launch of new products to diversify the company's portfolio.
The right issue's proceeds will be maintained in a designated bank account, overseen by the Audit Committee and subject to biannual auditor verification. This strategic financial maneuver is expected to strengthen Liven Pharma's market position and deliver enhanced returns to shareholders.